<b>Methods:</b> Randomized controlled trials (RCTs) in which patients with NAFLD were treated with SGLT-2 inhibitors or GLP-1 receptor agonists were included. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.